Graft Failure Clinical Trial
— PATENCYOfficial title:
PATency assessmENt of Grafts by Computerized tomographY in CORONARY Patients: the PATENCY-CORONARY Trial
Heart bypass surgery is used to increase blood flow to the heart. This surgery is usually done using a heart-lung machine (on-pump surgery) allowing the surgeon to perform the procedure on a still heart. However, this heart-lung machine causes an inflammatory response and is linked with complications such as heart injury, stroke, brain injury, kidney failure, need for blood transfusions, irregular heart rhythms and death. An effective way of counteracting the effects of the heart-lung machine is to not use the pump itself, thus performing the bypass surgery with a beating heart (off-pump surgery). However, off-pump surgery is technically more difficult, possibly associated with a decrease in graft patency. The ongoing Coronary Artery Bypass Graft Off or On Pump Revascularization Study (CORONARY), is a prospective randomized clinical trial comparing bypass surgery done with and without the pump. Worldwide, 4700 patients will be included and followed up for 5 years. The proposed research project, The Patency AssessmenT of grafts pErformed iN CORONARY (PATENCY-CORONARY), is a prospective clinical trial for the evaluation of patency (or "openness") of the bypass grafts that will enrol 1200 consecutive CORONARY patients reaching their one year follow-up. Patients will undergo a non-invasive scan using X-rays to safely and quickly evaluate graft patency. The PATENCY-CORONARY trial will determine if off-pump surgery is associated with decreased graft patency at 1-year post-surgery compared to on-pump surgery when performed by skilled surgeons in different clinical settings, whether decreased graft patency is associated with adverse short and long-term outcomes, and explore other risk factors associated with decreased graft patency.
Status | Unknown status |
Enrollment | 1200 |
Est. completion date | September 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: •All CORONARY (NCT00463294) patients reaching their one-year follow-up (9-24 months) will be included consecutively in the PATENCY-CORONARY trial. Exclusion Criteria: - Has a history of severe hypersensitivity to iodinated contrast agents; - Has known or suspected for pheochromocytoma; - Has severe renal impairment (estimated glomerular filtration rate, eGFR <35 mL/min/1.73 m2). Patients with eGFR 35-50 mL/min/1.73 m2 will be treated with hydratation and N-acetylcysteine (Mucomyst®) as per local protocol for contrast administration; - Has rapid atrial fibrillation or any other cardiac rhythm that precludes reliable ECG triggering; - Has severe congestive heart failure, New York Heart Association (NYHA) Class IV; - Is a pregnant or lactating female. |
Country | Name | City | State |
---|---|---|---|
Canada | Libin Cardiovascular Institute of Alberta | Calgary | Alberta |
Canada | Population Health Research Institute | Hamilton | Ontario |
Canada | Centre Hospitalier University de Montreal | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Centre hospitalier de l'Université de Montréal (CHUM) | Centre de Recherche du Centre Hospitalier de l'Université de Montréal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CABG Patency index | CABG patency index (i.e. the percentage of patent [non-occluded] distal anastomoses out of the total number of distal anastomoses for all patients) at 1 year after CABG surgery by experienced surgeons. | 12 months | |
Secondary | Graft lesion severity | Graft lesion severity on a 3-point scale at 1 year (mimicking the FitzGibbon grading ABO). | 12 months | |
Secondary | Patients with at least one occluded graft | Percentage of patients with at least one occluded bypass graft at 1 year. | 12 months | |
Secondary | Grafts compromised and clinical outcomes | Correlation between CTA findings (compromised grafts) with clinical primary outcomes of CORONARY trial (Myocardial infarct, Stroke, death), at one and five-year of follow-up post-CABG. | 12 months and 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT03663036 -
Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis
|
N/A | |
Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
Recruiting |
NCT04967391 -
Tumescence in HNC Skin Graft Reconstruction
|
Phase 3 | |
Recruiting |
NCT02061462 -
EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs
|
Phase 1 | |
Completed |
NCT01970605 -
Silver Graft All Comers Registry
|
||
Terminated |
NCT01564095 -
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
|
Phase 2/Phase 3 | |
Terminated |
NCT00208884 -
Terminal Graft Failure
|
N/A | |
Recruiting |
NCT04779957 -
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
|
Phase 2 | |
Terminated |
NCT04494061 -
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
|
||
Terminated |
NCT04731298 -
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
|
Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02556879 -
Immunization Anti HLA in the Liver Transplant Recipients (DSATH)
|
N/A | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Recruiting |
NCT00472329 -
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT04542954 -
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
|
||
Recruiting |
NCT03717545 -
Second Transplantation for Graft Failure
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Recruiting |
NCT01631058 -
Renal Transplantation in the Elderly - nEverOld Study
|
Phase 4 | |
Completed |
NCT06340607 -
Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
|